Non-vitamin K antagonist oral anticoagulants and sport

被引:2
|
作者
Romano, Silvio [1 ]
Salustri, Elisa [1 ]
Robles, Antonio G. [2 ]
Calo, Leonardo [2 ]
Penco, Maria [1 ]
Sciarra, Luigi [2 ]
机构
[1] Univ Aquila, Dept Life Hlth & Environm Sci, Laquila, Italy
[2] Casilino Polyclin Hosp, Dept Cardiol, Rome, Italy
来源
MINERVA CARDIOANGIOLOGICA | 2020年 / 68卷 / 02期
关键词
Pharmacologic actions; Athletes; Anticoagulants; Atrial fibrillation; FACTOR XA INHIBITOR; POTENTIALLY ARRHYTHMOGENIC CONDITIONS; ATRIAL-FIBRILLATION PATIENTS; TIME PHYSICAL-ACTIVITY; CARDIAC REHABILITATION; COMPETITIVE SPORTS; ANTITHROMBOTIC THERAPY; STROKE PREVENTION; RISK-FACTORS; DABIGATRAN;
D O I
10.23736/S0026-4725.20.05177-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Physical activity is worldwide recommended for its benefits on cardiovascular system. There is an increasing number of people of all ages that approach sport activity both as leisure time physical activity and as competitive sport. It is always more frequent the request even from older subjects and cardiac patients to be allowed to practice physical activity. Some problems could arise when these subjects present or develop pathologic conditions that require specific pharmacological treatment, in particular an anticoagulation therapy. This review focalizes on the manaaement of oral anticoagulant therapy (OAT) in patients practicing sport activity, especially due to atrial fibrillation and deep vein thrombosis, which represent two highly prevalent conditions, particularly with increasing age. Official recommendations in this field may appear limiting for patients, forbidding in the majority of cases sports at risk of trauma and consequent bleeding. These recommendations still resent the heritage of the "traditional" management of OAT, mainly represented by vitamin-K antagonists (VKAs). The non-vitamin K antagonist oral anticoagulants, with their more favorable pharmacokinetic-pharmacodynamic profile compare to VKAs, may now represent an opportunity to modify the approach to sport activity in patients with an indication to OAT. This review of the literature deals with possible strategies to overcome the present limitations for OAT subjects willing to pursue a healthy lifestyle, that include sport activity, minimizing at the same time their risk of bleeding.
引用
收藏
页码:98 / 109
页数:12
相关论文
共 50 条
  • [1] Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
    Malagu, Michele
    Longo, Filomena
    Marchini, Federico
    Sirugo, Paolo
    Capanni, Andrea
    Clo, Stefano
    Mari, Elisa
    Culcasi, Martina
    Bertini, Matteo
    [J]. BIOLOGY-BASEL, 2023, 12 (04):
  • [2] Non-vitamin K antagonist oral anticoagulants and heart failure
    Isnard, Richard
    Bauer, Fabrice
    Cohen-Solal, Alain
    Damy, Thibaud
    Donal, Erwan
    Galinier, Michel
    Hagege, Albert
    Jourdain, Patrick
    Leclercq, Christophe
    Sabatier, Remi
    Trochu, Jean-Noel
    Cohen, Ariel
    [J]. ARCHIVES OF CARDIOVASCULAR DISEASES, 2016, 109 (11) : 641 - 650
  • [3] Reversal agents for non-vitamin K antagonist oral anticoagulants
    Levy, Jerrold H.
    Douketis, James
    Weitz, Jeffrey I.
    [J]. NATURE REVIEWS CARDIOLOGY, 2018, 15 (05) : 273 - 281
  • [4] Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
    Plitt, Anna
    Ruff, Christian T.
    Giugliano, Robert P.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (05) : 1019 - +
  • [5] NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH THALASSEMIA
    Capanni, A.
    Clo, S.
    Sirugo, P.
    Guardigli, G.
    Bertini, M.
    Orazio, G.
    Malagu, M.
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2023, 25
  • [6] Reversal agents for non-vitamin K antagonist oral anticoagulants
    Jerrold H. Levy
    James Douketis
    Jeffrey I. Weitz
    [J]. Nature Reviews Cardiology, 2018, 15 : 273 - 281
  • [7] Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome
    Sciascia, Savino
    Lopez-Pedrera, Chary
    Cecchi, Irene
    Pecoraro, Clara
    Roccatello, Dario
    Cuadrado, Maria Jose
    [J]. RHEUMATOLOGY, 2016, 55 (10) : 1726 - 1735
  • [8] Non-vitamin K antagonist oral anticoagulants for heart diseases
    Kondratieva, T. B.
    Popova, L. V.
    Bokarev, I. N.
    [J]. TERAPEVTICHESKII ARKHIV, 2017, 89 (09): : 120 - 127
  • [9] Non-vitamin K antagonist oral anticoagulants and infective endocarditis
    Caldeira, Daniel
    Ferreira, Joaquim J.
    Pinto, Fausto J.
    Costa, Joao
    [J]. HEART, 2018, 104 (13) : 1135 - 1136
  • [10] Pros and Cons of Vitamin K Antagonists and Non-Vitamin K Antagonist Oral Anticoagulants
    Riva, Nicoletta
    Ageno, Walter
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2015, 41 (02): : 178 - 187